Trading Signals: ABBV Stock Price Prediction and Forecast (Mon. Mar. 17, 2014 - Fri. Dec. 22, 2023)(AbbVie Inc.)
| ABBV latest price $80.7398 (2.92%) ($78.6948 - $82.1821) on Thu. Oct. 25, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 1.61% (three month average) | RSI | 28 | Latest Price | $80.7398(2.92%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ABBV declines -1.9% a day on average for past five trading days. | Weekly Trend | ABBV declines -5.2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ABBV advance at 0% a week (0% probability) XLV(61%) VYM(51%) IVE(49%) SPLV(49%) IWD(48%) | Factors Impacting ABBV price | ABBV will decline at least -0.805% in a week (0% probabilities). TLT(-14%) VXX(-13%) VIXM(-13%) UUP(-11%) DIA(-10%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -0.805% (StdDev 1.61%) | Hourly BBV | 0 () | Intraday Trend | 1.7% | | | |
|
1 - 5 Day Possible Target | $75.3(-6.74%) | Resistance Level | $88.75 | 5 Day Moving Average | $82.26(-1.85%) | 10 Day Moving Average | $85.74(-5.83%) | 20 Day Moving Average | $88.75(-9.03%) | To recent high | -16.4% | To recent low | 2.9% | Market Cap | $142.448b | | | | AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. |